Pregnancy: There are no adequate data from the use of Fosrenol in pregnant women.
One study in rats showed reproductive foetotoxicity (delayed eye opening and sexual maturation) and reduced pup weights at high doses (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown. Fosrenol is not recommended for use during pregnancy.
Breast-feeding: It is unknown whether lanthanum is excreted in human breast milk. The excretion of lanthanum in milk has not been studied in animals. Caution should be used in taking a decision whether to continue/discontinue breast feeding or to continue/discontinue therapy with Fosrenol, taking into account the potential benefit of breast feeding to the child and the potential benefit of Fosrenol therapy to the nursing mother.
Fertility: There are no fertility data available on lanthanum carbonate in humans. In rat toxicology studies, lanthanum carbonate had no adverse effects on fertility.